Susquehanna International Group
FDMT icon

Susquehanna International Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Susquehanna International Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$451K Buy
48,400
+16,900
+54% +$147K ﹤0.01% 9943
2025
Q4 		$236K Buy
31,500
+8,600
+38% +$87.2K ﹤0.01% 10498
2025
Q3 		$199K Buy
+22,900
New +$137K ﹤0.01% 11001
2025
Q1 		– Sell
-74,400
Closed -$414K – 12758
2024
Q4 		$414K Sell
74,400
-24,400
-25% -$191K ﹤0.01% 9130
2024
Q3 		$1.07M Buy
98,800
+49,100
+99% +$815K ﹤0.01% 6638
2024
Q2 		$1.04M Sell
49,700
-132,400
-73% -$3.32M ﹤0.01% 6481
2024
Q1 		$5.8M Buy
182,100
+136,000
+295% +$3.47M ﹤0.01% 3409
2023
Q4 		$934K Buy
46,100
+28,000
+155% +$368K ﹤0.01% 7145
2023
Q3 		$230K Sell
18,100
-32,300
-64% -$540K ﹤0.01% 9917
2023
Q2 		$911K Sell
50,400
-17,500
-26% -$322K ﹤0.01% 6901
2023
Q1 		$1.17M Buy
67,900
+17,700
+35% +$344K ﹤0.01% 6410
2022
Q4 		$1.11M Buy
+50,200
New +$775K ﹤0.01% 5928
2022
Q3 		– Sell
-36,600
Closed -$255K – 13445
2022
Q2 		$255K Buy
36,600
+700
+2% +$6.8K ﹤0.01% 9996
2022
Q1 		$543K Buy
+35,900
New +$564K ﹤0.01% 8763

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's FDMT Position: Q1 2026 in Review

Susquehanna International Group reduced its 4D Molecular Therapeutics (FDMT) stake by 1.4% in Q1 2026, selling an estimated $15.5K and leaving 124,228 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #7501.

Susquehanna International Group first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.35M in Q1 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Susquehanna International Group held 124,228 shares of 4D Molecular Therapeutics worth $1.16M as of Q1 2026.
  • Susquehanna International Group sold 1,785 4D Molecular Therapeutics shares in Q1 2026, an estimated $15.5K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7501 holding.
  • Susquehanna International Group first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Susquehanna International Group's 4D Molecular Therapeutics position peaked at $1.35M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.